by Nicholas J. White, Tran T. Duong, Chirapong Uthaisin et al.
N Engl J Med 2016; 375:1152-1160, September 22, 2016
9 pp. 283 kB
Expanding artemisinin resistance and worsening partner-drug resistance in Southeast Asia threaten the global control of Plasmodium falciparum malaria. New drugs are needed. KAF156 represents a new class of antimalarial agents (imidazolopiperazines).The authors conclude that KAF156 showed antimalarial activity without evident safety concerns in a small number of adults with uncomplicated P. vivax or P. falciparum malaria.